Literature DB >> 26724397

More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy.

Ahmed ElShafei1, Yaw Nyame2, Onder Kara2, Atef Badawy3, Ifeanyi Amujiogu2, Khaled Fareed2, Eric Klein2, J Stephen Jones4.   

Abstract

PURPOSE: We assessed the pathological outcomes after radical prostatectomy in men with favorable risk prostate cancer diagnosed on first/initial biopsy compared to those of men who were diagnosed on a subsequent/repeat prostate biopsy.
MATERIALS AND METHODS: We identified 422 patients who met National Comprehensive Cancer Network® very low (199) and low risk (223) prostate cancer definitions who instead underwent radical prostatectomy. In each risk category we compared adverse pathological outcomes, defined as Gleason score upgrading, extraprostatic extension, seminal vesicle invasion and positive surgical margins, between men diagnosed on initial prostate biopsy vs repeat/subsequent prostate biopsy after a negative biopsy(-ies).
RESULTS: There were no significant differences in the baseline clinical and demographic characteristics between the groups. However, men who were diagnosed on initial prostate biopsy demonstrated a higher median maximum cancer percent per single core (p <0.001) and higher median percent of positive cores (p <0.001). Compared to repeat/subsequent prostate biopsy, men diagnosed on initial prostate biopsy had a higher Gleason score upgrade (7 or greater) (57.7% vs 42.1%, p=0.005) and extraprostatic extension (14.1% vs 5.4%, p=0.01). On stratified analysis comparing initial prostate biopsy to repeat/subsequent prostate biopsy, very low risk disease was associated with Gleason score upgrade (49.3% vs 31.8%, p=0.02) and low risk disease demonstrated higher rates of extraprostatic extension (19.9% vs 6.0%, p=0.02).
CONCLUSIONS: The likelihood of adverse pathological outcomes at radical prostatectomy is lower in men diagnosed with favorable risk prostate cancer on repeat/subsequent prostate biopsy than in men diagnosed on initial prostate biopsy, and may represent an important consideration in risk stratifying cases of favorable risk prostate cancer.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; prostatectomy; prostatic neoplasms; risk; watchful waiting

Mesh:

Year:  2015        PMID: 26724397     DOI: 10.1016/j.juro.2015.12.079

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Active surveillance before radiotherapy: Outcome and predictive factors for multiple biopsies before treatment.

Authors:  Alexandre Alcaidinho; Guila Delouya; Jean-Paul Bahary; Fred Saad; Daniel Taussky
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

2.  Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

Authors:  James T Kearns; Anna V Faino; Lisa F Newcomb; James D Brooks; Peter R Carroll; Atreya Dash; William J Ellis; Michael Fabrizio; Martin E Gleave; Todd M Morgan; Peter S Nelson; Ian M Thompson; Andrew A Wagner; Yingye Zheng; Daniel W Lin
Journal:  Eur Urol       Date:  2018-02-09       Impact factor: 20.096

3.  Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer.

Authors:  Mattia Luca Piccinelli; Stefano Luzzago; Giulia Marvaso; Ekaterina Laukhtina; Noriyoshi Miura; Victor M Schuettfort; Keiichiro Mori; Alberto Colombo; Matteo Ferro; Francesco A Mistretta; Nicola Fusco; Giuseppe Petralia; Barbara A Jereczek-Fossa; Shahrokh F Shariat; Pierre I Karakiewicz; Ottavio de Cobelli; Gennaro Musi
Journal:  World J Urol       Date:  2022-03-26       Impact factor: 3.661

4.  Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Todd M Morgan; Simpa S Salami; Scott A Tomlins; Daniel E Spratt; Javed Siddiqui; Lakshmi P Kunju; Rachel Botbyl; Zoey Chopra; Balaji Pandian; Nicholas W Eyrich; Gary Longton; Yingye Zheng; Ganesh S Palapattu; John T Wei; Yashar S Niknafs; Arul M Chinnaiyan
Journal:  J Urol       Date:  2020-10-20       Impact factor: 7.450

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.